---
---

# 21 U.S.C., USLM ref /us/usc/t21/s360bbb–5

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptE/m__us_usc_t21_s360bbb–4.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptE/m__us_usc_t21_s360bbb–6.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs360bbb%E2%80%935)

## § 360bbb–5. Critical Path Public-Private Partnerships

    (a) __Establishment__ 

        The Secretary, acting through the Commissioner of Food and Drugs, may enter into collaborative agreements, to be known as Critical Path Public-Private Partnerships, with one or more eligible entities to implement the Critical Path Initiative of the Food and Drug Administration by developing innovative, collaborative projects in research, education, and outreach for the purpose of fostering medical product innovation, enabling the acceleration of medical product development, manufacturing, and translational therapeutics, and enhancing medical product safety.

    (b) __Eligible entity__ 

    In this section, the term “eligible entity” means an entity that meets each of the following:

        (1)

         The entity is—

            (A) an institution of higher education (as such term is defined in [section 1001 of title 20][/us/usc/t20/s1001]) or a consortium of such institutions; or

            (B) an organization described in [section 501(c)(3) of title 26][/us/usc/t26/s501/c/3] and exempt from tax under section 501(a) of such title.

        (2) The entity has experienced personnel and clinical and other technical expertise in the biomedical sciences, which may include graduate training programs in areas relevant to priorities of the Critical Path Initiative.

        (3)

         The entity demonstrates to the Secretary’s satisfaction that the entity is capable of—

            (A)

             developing and critically evaluating tools, methods, and processes—

                (i) to increase efficiency, predictability, and productivity of medical product development; and

                (ii) to more accurately identify the benefits and risks of new and existing medical products;

            (B) establishing partnerships, consortia, and collaborations with health care practitioners and other providers of health care goods or services; pharmacists; pharmacy benefit managers and purchasers; health maintenance organizations and other managed health care organizations; health care insurers; government agencies; patients and consumers; manufacturers of prescription drugs, biological products, diagnostic technologies, and devices; and academic scientists; and

            (C) securing funding for the projects of a Critical Path Public-Private Partnership from Federal and nonfederal governmental sources, foundations, and private individuals.

    (c) __Funding__ 

        The Secretary may not enter into a collaborative agreement under subsection (a) unless the eligible entity involved provides an assurance that the entity will not accept funding for a Critical Path Public-Private Partnership project from any organization that manufactures or distributes products regulated by the Food and Drug Administration unless the entity provides assurances in its agreement with the Food and Drug Administration that the results of the Critical Path Public-Private Partnership project will not be influenced by any source of funding.

    (d) __Annual report__ 

    Not later than 18 months after September 27, 2007, and annually thereafter, the Secretary, in collaboration with the parties to each Critical Path Public-Private Partnership, shall submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives—

        (1) reviewing the operations and activities of the Partnerships in the previous year; and

        (2) addressing such other issues relating to this section as the Secretary determines to be appropriate.

    (e) __Definition__ 

        In this section, the term “medical product” includes a drug, a biological product as defined in [section 262 of title 42][/us/usc/t42/s262], a device, and any combination of such products.

    (f) __Authorization of appropriations__ 

        To carry out this section, there is authorized to be appropriated $6,000,000 for each of fiscal years 2013 through 2017.

([June 25, 1938, ch. 675, § 566][/us/act/1938-06-25/ch675/s566], as added [Pub. L. 110–85, title VI, § 603][/us/pl/110/85/s603], Sept. 27, 2007, [121 Stat. 898][/us/stat/121/898]; amended [Pub. L. 112–144, title XI, § 1102][/us/pl/112/144/s1102], July 9, 2012, [126 Stat. 1108][/us/stat/126/1108].)

 __Amendments__ 

    2012—Subsec. (f). [Pub. L. 112–144][/us/pl/112/144] amended subsec. (f) generally. Prior to amendment, text read as follows: “To carry out this section, there are authorized to be appropriated $5,000,000 for fiscal year 2008 and such sums as may be necessary for each of fiscal years 2009 through 2012.”

----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptE/m__us_usc_t21_s360bbb–4.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptE/m__us_usc_t21_s360bbb–6.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs360bbb%E2%80%935)

----------
----------

[/us/usc/t20/s1001]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft20%2Fs1001
[/us/usc/t26/s501/c/3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft26%2Fs501%2Fc%2F3
[/us/usc/t42/s262]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs262
[/us/act/1938-06-25/ch675/s566]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675%2Fs566
[/us/pl/110/85/s603]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F110%2F85%2Fs603
[/us/stat/121/898]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F121%2F898
[/us/pl/112/144/s1102]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2Fs1102
[/us/stat/126/1108]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F126%2F1108
[/us/pl/112/144]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144


